Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
IDENIX PHARMACEUTICALS INC (IDIX)
|
Add to portfolio |
|
|
|
| Price: |
$5.50
| | Metrics |
| OS: |
151.5
|
M
| |
|
|
| Market cap: |
$833
|
M
| |
|
|
|
Net cash:
|
$178
|
M
| |
$1.17
|
per share
|
|
EV:
|
$656
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 0.5 | 69.7 | 7.0 | 10.2 | 12.6 | 10.0 | 68.0 | 67.4 |
| Revenue growth | -99.3% | 902.2% | -32.0% | -19.0% | 25.5% | -85.2% | 1.0% | 4.1% |
| Cost of goods sold | 0.7 | 2.7 | 2.3 | 2.8 | 2.2 | 1.7 | 2.0 | 0.1 |
| Gross profit | -0.2 | 67.0 | 4.6 | 7.5 | 10.4 | 8.3 | 66.0 | 67.3 |
| Gross margin | -52.5% | 96.2% | 66.6% | 73.0% | 82.5% | 82.6% | 97.1% | 99.9% |
| Selling, general and administrative | | | | | | | | 57.0 |
| Research and development | 84.3 | 70.2 | 41.3 | 44.5 | 41.9 | 53.9 | 85.8 | |
| General and administrative | 35.3 | 24.2 | 16.7 | 23.4 | 21.5 | 27.1 | 63.3 | |
| EBIT | -117.5 | -27.3 | -53.4 | -60.5 | -52.9 | -72.7 | -83.2 | -85.7 |
| EBIT margin | -25057.6% | -39.2% | -768.3% | -591.7% | -419.5% | -723.6% | -122.2% | -127.2% |
| Pre-tax income | -122.4 | -32.5 | -52.0 | -61.6 | -53.2 | -70.2 | 82.3 | -76.2 |
| Income taxes | -0.1 | -0.1 | -0.1 | 0.0 | 0.1 | 0.0 | -0.2 | -1.1 |
| Tax rate | 0.1% | 0.3% | 0.1% | 0.1% | | | | 1.5% |
| Net income | -122.3 | -32.4 | -52.0 | -61.6 | -53.2 | -70.2 | -82.5 | -75.1 |
| Net margin | -26074.0% | -46.5% | -747.8% | -602.2% | -421.8% | -698.6% | -121.3% | -111.4% |
| |
| Diluted EPS | ($0.91) | ($0.27) | ($0.57) | ($0.87) | ($0.87) | ($1.24) | ($1.47) | ($1.34) |
| Shares outstanding (diluted) | 134.0 | 118.8 | 90.8 | 70.7 | 61.5 | 56.4 | 56.2 | 56.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|